What are the results of the clinical trial data analysis of trametinib?

Trametinib is a highly selective MEK inhibitor that inhibits the proliferation and survival of tumor cells by blocking the activity of MEK1 and MEK2 in the RAS/RAF/MEK/ERK signaling pathway. Globally, trametinib has launched multiple clinical trials against a variety of BRAF mutation-related malignancies, including unresectable or metastatic melanoma, BRAF V600E-mutated non-small cell lung cancer (NSCLC), anaplastic thyroid cancer (ATC), etc.

Judging from overseas clinical trial data, trametinib alone can bring a higher objective response rate (ORR) and longer progression-free survival (PFS) in BRAF V600E or V600K mutated melanoma. However, its monotherapy often leads to drug resistance due to feedback activation of the MAPK pathway. Therefore, in subsequent studies, more trials choose to use it in combination with BRAF inhibitors such as dabrafenib to delay the occurrence of drug resistance and improve efficacy.

In other tumor types such as NSCLC and ATC, trametinib also shows certain anti-tumor activity, especially in the dabrafenib combination regimen, the effect is more significant. Some real-world data are consistent with clinical trial results, showing that combination therapy not only improves response rates, but also improves disease control rates and patient quality of life.

In terms of safety, common adverse reactions of trametinib include rash, diarrhea, peripheral edema, decreased cardiac function, and ocular toxicity. Most of them can be controlled through dose adjustment, symptomatic treatment, and monitoring. In large-sample analysis, its safety profile was consistent with previous clinical trial results, and no new major risk signals were found.

In general, trametinib has been proven effective in multiple malignant tumor types, especially in the context of BRAF mutations Its combined use with BRAF inhibitors has become one of the first-line treatments recommended by international guidelines

Reference materials:https://go.drugbank.com/drugs/DB08911